August 11, 2026
NeuroVision Featured in Practical Neurology's Review of AI in Clinical Neurology
"Neurodiscovery AI has been instrumental in transforming real-world neurology data into actionable insights that improve patient care and sustain private practice. Their commitment to neurologists—ensuring both business success and innovation in drug discovery—makes them an invaluable partner to NeuroNet and the entire field of community neurology."
Joseph V. Fritz PhDPartner,
NeuroDiscovery AI's NeuroVision platform has been recognized in Practical Neurology's landmark review, "Artificial Intelligence in Clinical Neurology: Opportunities, Limitations, and the Path Forward." The comprehensive article highlights NeuroVision's advanced capabilities in analyzing critical imaging biomarkers for neurological conditions, positioning it among the leading AI-powered neuroimaging solutions advancing clinical practice.
NeuroVision Capabilities:
- Alzheimer's Disease: Automated detection and monitoring of ARIA (Amyloid-Related Imaging Abnormalities), supporting safer anti-amyloid therapy management.
- Multiple Sclerosis: Precise detection and quantification of subtle MS lesions to track longitudinal disease progression and treatment response.
- Clinical Integration: Enterprise-grade imaging analysis designed specifically for neurology workflows.
Platform Availability
NeuroVision is currently available as a beta version at no cost to all US neurologists and neurology groups, democratizing access to advanced clinical AI tools that were previously available only to large academic medical centers.
Clinical Context
The Practical Neurology review examines how AI is revolutionizing clinical neuroimaging by enhancing diagnostic accuracy, enabling faster interpretation of complex scans, and supporting clinical decision-making in neurology and neurosurgery. NeuroVision's recognition in this comprehensive analysis validates our platform's role in addressing real-world clinical challenges while maintaining neurologists at the center of patient care.
What This Means for Providers
This independent recognition in a leading neurology publication underscores NeuroVision's clinical utility and reliability. The platform provides neurologists with AI-augmented insights for critical diagnostic decisions, disease monitoring, and treatment optimization without additional cost barriers.
Access NeuroVision: US-based neurologists and neurology practices can request access to NeuroVision through our provider portal or by contacting our clinical team.
FAQs
-
What is NeuroVision?
NeuroVision is NeuroDiscovery AI's AI-powered neuroimaging platform, designed to analyze critical imaging biomarkers for neurological conditions such as Alzheimer's disease and multiple sclerosis.
-
What did Practical Neurology's review say about NeuroVision?
Practical Neurology featured NeuroVision in its comprehensive review, "Artificial Intelligence in Clinical Neurology: Opportunities, Limitations, and the Path Forward," highlighting its imaging biomarker capabilities as among the leading AI-powered neuroimaging solutions in clinical practice.
-
What can NeuroVision detect for Alzheimer's disease?
NeuroVision automatically detects and monitors ARIA (Amyloid-Related Imaging Abnormalities), helping support safer management of anti-amyloid therapies.
-
How does NeuroVision support multiple sclerosis care?
NeuroVision precisely detects and quantifies subtle MS lesions, helping clinicians track longitudinal disease progression and treatment response.
-
Is NeuroVision available to all neurologists, and what does it cost?
NeuroVision is currently available as a beta version at no cost to all US neurologists and neurology groups, giving practices of any size access to imaging tools that were previously limited to large academic medical centers.
-
How can a neurology practice access NeuroVision?
US-based neurologists and neurology practices can request access through NeuroDiscovery AI's provider portal or by contacting the clinical team directly.
